Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Total Debt
Short-term and long-term borrowings combined.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 35.6% from a year ago
Total debt stood at $941K at the end of Q1 FY2026, up 35.6% from a year earlier and up 372.9% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.
Context
- Total debt amounted to 1.5% of total assets at the end of Q1 FY2026, down 1.0 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +35.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 199K USD
- Year-over-year change
- -74.3%
- 4-year CAGR
- -12.2%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 199K | -74.3% |
| FY2024 | 2024-12-31 | 773K | -4.7% |
| FY2023 | 2023-12-31 | 811K | +303.5% |
| FY2022 | 2022-12-31 | 201K | -40.0% |
| FY2021 | 2021-12-31 | 335K | — |
Total Debt vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +35.6% is the 2nd highest of 9, against a peer median of -64.7%.
- Total debt amounts to 1.5% of total assets for UNCY, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $276.15M USD | +674.7% | +168.1% | 85.2% |
| Mar 2026 | $7.97M USD | -52.6% | -31.1% | 4.4% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$3.55M CAD | -72.5% | +69.2% | 15.3% |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $2.42M USD | -31.3% | -18.3% | 2.2% |
| Mar 2026 | $2.12M USD | -73.0% | — | 2.0% | |
| Mar 2026 | $1.24M USD | -84.4% | -11.4% | 2.7% | |
| Mar 2026 | $941K USD | +35.6% | -0.3% | 1.5% | |
| Mar 2026 | $421K USD | -56.8% | -24.1% | 0.2% | |
| Mar 2026 | $293K USD | -73.5% | -60.9% | 0.3% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UNCY) | — | -64.7% | -18.3% | 2.2% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.